디지털 의약품 공급망 관리 : 시장 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the digital pharmaceutical supply chain management market size was valued at USD 1.21 billion in 2025 and is estimated to grow from USD 1.35 billion in 2026 to reach USD 2.41 billion by 2031, at a CAGR of 12.18% during the forecast period (2026-2031).

This report is Segmented by Component (Software, Services, and Hardware), Application (Inventory & Warehouse Management, and More), Deployment (Cloud-Based, and More), Technology (RFID & 2D Barcoding, and More), Service Type (Implementation & Integration, and More), End User (Pharmaceutical Companies, and More), and Geography. The Market and Forecasted in Terms of Value (USD).

Global Digital Pharmaceutical Supply Chain Management Market Trends and Insights

Rising Pharmaceutical Serialization & Track-and-Trace Mandates

Global regulators are tightening unit-level serialization rules, compelling manufacturers and distributors to upgrade legacy pedigree platforms to cloud-ready, GS1-compliant solutions before the November 2027 DSCSA interoperability deadline. In 2025, TraceLink reported that 323 contract manufacturing organizations were in active EPCIS testing, while 100 reached production-ready status, signaling an industry-wide sprint toward standardized partner onboarding. SAP and Oracle secured multiple early adopter contracts for their serialization suites, marking an enterprise software replacement cycle as firms abandon proprietary barcodes for 2D data matrices. Divergent regional standards intensify complexity, prompting distributors that span multiple jurisdictions to adopt multi-tenant platforms able to switch identifiers in real time. Vertical integration is accelerating as wholesalers embed track-and-trace capabilities directly into distribution agreements to retain brand-owner relationships.

Cloud-Native & AI-Driven Supply-Chain Orchestration

Pharmaceutical companies are shifting planning and execution workloads from on-premise ERP stacks to elastic cloud platforms that infuse machine learning into demand forecasting and inventory optimization. Sanofi's AI-enabled tool averted USD 300 million in revenue risk in 2025 by flagging low-stock events with 80% accuracy, cutting expedited freight costs by up to 28%. Pfizer used a digital twin to unlock more than 3 million extra doses without brick-and-mortar expansion. Roche paired NVIDIA GPUs with lab-in-the-loop workflows to simulate manufacturing steps, signaling a pivot toward compute-rich factories. Generative AI tools such as AstraZeneca's AskAZ cut manual lab-request coordination by 30,000 hours in 2025, showing that conversational agents can collapse procurement cycles into a same-day activity. For patient-specific cell-and-gene therapies, SAP's orchestration release now coordinates apheresis bookings, viral vector runs, and hospital infusions along a contiguous chain of custody.

High Integration & Change-Management Costs

Moving from legacy manufacturing execution systems to cloud stacks can cost between USD 5 million and USD 50 million, with validation cycles stretching 18-36 months under FDA 21 CFR Part 11 and EU Annex 11. Chanelle Pharma expects 14 months of dual-run operations during its S/4HANA upgrade, illustrating the operational risk burden on smaller firms. CMOs shoulder an asymmetric load because they must keep interfaces live for dozens of brand owners, each with its own aggregation hierarchy. This pressure triggers consolidation as sub-scale CMOs lose bids to rivals offering turnkey EPCIS compliance. Consumption-based pricing from TraceLink, Optel, and Korber spreads integration costs across transaction volumes, easing capital strain but increasing dependency on outsourced operators.

Other drivers and restraints analyzed in the detailed report include:

1. Growth of Biologics, Cell-&-Gene Therapies Requiring Cold-Chain
2. Surge in DSCSA Interoperability & EPCIS 1.2 Deployments
3. Cyber-Security Risk in Connected Logistics Networks

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Software captured 56.81% digital pharmaceutical supply chain management market share in 2025 as enterprises favored feature-rich serialization suites that comply with global data-residency rules. Services, though smaller, are advancing at a 14.57% CAGR and are projected to account for a growing slice of the digital pharmaceutical supply chain management market size by 2031 because vendors roll hardware, licenses, and change-management into single per-unit fees. Hardware trails yet gains from embedded IoT sensors that feed real-time cold-chain data to cloud dashboards, minimizing spoilage risk.

SAP, Oracle, and IBM are steering software toward cloud-native formats that deploy anomaly detection and predictive maintenance, while TraceLink bundles 99.9% uptime SLAs into managed contracts, shifting cyber-liability away from drug makers. Hardware growth clusters around cryogenic depots like Cryoport's Paris center, where sensor-rich freezers stream telemetry at five-minute intervals. The divergence signals a long-term migration from capital purchases to pay-as-you-go services that scale with product volumes.

Inventory and warehouse management held 27.47% of 2025 revenues, yet drug traceability and serialization are forecast to log a 13.28% CAGR and become the fastest-growing slice of the digital pharmaceutical supply chain management market size between 2026 and 2031. Transportation modules benefit from biologics cold-chain demand, while AI-driven demand-planning engines secure executive attention after Sanofi's cost-avoidance case study.

The serialization boom reflects a one-time compliance shock as firms scrap proprietary e-pedigree tools in favor of GS1 DataMatrix and EPCIS 1.2 flows. Vendors compete on onboarding speed, with TraceLink cutting CMO partner ramp-up windows to six months. Warehouse solutions now embed dynamic slotting algorithms that adapt to real-time order queues, whereas transportation modules differentiate on minute-by-minute temperature visibility via Controlant Saga cards.

Geography Analysis

North America held 36.65% of 2025 revenue and remains the anchor of the digital pharmaceutical supply chain management market due to DSCSA enforcement plus USD 13.6 billion in pharma IT outlays. IBM's Pulse already fields more than 1 million verification calls annually and TraceLink's CMO network solidifies the region's leadership. Near-shoring pushes investments into Canada and Mexico, while ESG-linked financing, such as Energize's power purchase pact, drives sustainability metrics into sourcing decisions.

Asia-Pacific delivers the fastest CAGR at 16.59%, led by large-ticket biologics projects from Pfizer Wuhan, Takeda Osaka, and Samsung Biologics Songdo. India's USD 3 billion incentive pipeline plus Japan's preference for on-premise execution shapes the regional deployment mix. Cryogenic networks expand to service growing cell-therapy corridors, with Cryoport and World Courier adding depots in Singapore and Melbourne.

Europe benefits from the Critical Medicines Act and Falsified Medicines Directive, posting a significant share while leaning toward hybrid deployments to meet data-residency rules. Novo Nordisk, Sanofi, and AstraZeneca pour more than USD 10 billion combined into capacity, while banks finance green warehouses in Egypt and Saudi Arabia to shore up regional resiliency. South America edges forward as ANVISA aligns serialization codes with United States and European Union frameworks, though adoption pace lags due to integration cost barriers.

1. Antares Vision Group
2. Arvato Supply Chain Solutions
3. AVERY DENNISON
4. Blue Yonder Group, Inc.
5. Cardinal Health
6. Exostar, LLC
7. Global Healthcare Exchange, LLC (GHX)
8. IBM
9. Infor Global Solutions
10. Kinaxis Inc.
11. Korber Pharma Software GmbH
12. Manhattan Associates, Inc.
13. Mckesson
14. Optel Group
15. Oracle
16. project44, Inc.
17. SAP
18. Tecsys Inc.
19. TraceLink, Inc.
20. UPS Healthcare

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rising Pharmaceutical Serialization & Track-and-Trace Mandates
  • 4.2.2 Cloud-Native & AI-driven Supply-Chain Orchestration
  • 4.2.3 Growth of Biologics, Cell-&-Gene Therapies Requiring Cold-Chain
  • 4.2.4 Near-Shoring & Dual-Sourcing of API/finished-Dose Production
  • 4.2.5 Surge in DSCSA Interoperability & EPCIS 1.2 Deployments
  • 4.2.6 ESG-linked Supply-Chain Financing Incentives
• 4.3 Market Restraints
  • 4.3.1 High Integration & Change-Management Costs
  • 4.3.2 Multi-Jurisdiction Compliance Complexity
  • 4.3.3 Legacy IT & Data-Silo Technical Debt
  • 4.3.4 Cyber-Security Risk in Connected Logistics Networks
• 4.4 Value / Supply-Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porters Five Forces Analysis
  • 4.7.1 Threat of New Entrants
  • 4.7.2 Bargaining Power of Buyers
  • 4.7.3 Bargaining Power of Suppliers
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Competitive Rivalry

5 Market Size & Growth Forecasts (Value, USD)

• 5.1 By Component
  • 5.1.1 Software
  • 5.1.2 Services
  • 5.1.3 Hardware
• 5.2 By Application
  • 5.2.1 Inventory & Warehouse Management
  • 5.2.2 Drug Traceability & Serialization
  • 5.2.3 Transportation & Logistics Management
  • 5.2.4 Demand Forecasting & Planning
  • 5.2.5 Compliance & Risk Management
  • 5.2.6 Others
• 5.3 By Deployment
  • 5.3.1 Cloud-based
  • 5.3.2 On-premise
  • 5.3.3 Hybrid
• 5.4 By Technology
  • 5.4.1 RFID & 2D Barcoding
  • 5.4.2 IoT Sensors & Edge Devices
  • 5.4.3 Blockchain & Distributed Ledger
  • 5.4.4 Advanced Analytics & AI/ML
  • 5.4.5 Others
• 5.5 By Service Type
  • 5.5.1 Implementation & Integration
  • 5.5.2 Managed Services
  • 5.5.3 Consulting & Training
  • 5.5.4 Others
• 5.6 By End User
  • 5.6.1 Pharmaceutical Companies
  • 5.6.2 Biotechnology Companies
  • 5.6.3 Contract Manufacturing Organizations (CMOs)
  • 5.6.4 Others
• 5.7 By Geography
  • 5.7.1 North America
    • 5.7.1.1 United States
    • 5.7.1.2 Canada
    • 5.7.1.3 Mexico
  • 5.7.2 Europe
    • 5.7.2.1 Germany
    • 5.7.2.2 United Kingdom
    • 5.7.2.3 France
    • 5.7.2.4 Italy
    • 5.7.2.5 Spain
    • 5.7.2.6 Rest of Europe
  • 5.7.3 Asia-Pacific
    • 5.7.3.1 China
    • 5.7.3.2 India
    • 5.7.3.3 Japan
    • 5.7.3.4 Australia
    • 5.7.3.5 South Korea
    • 5.7.3.6 Rest of Asia-Pacific
  • 5.7.4 Middle East and Africa
    • 5.7.4.1 GCC
    • 5.7.4.2 South Africa
    • 5.7.4.3 Rest of Middle East and Africa
  • 5.7.5 South America
    • 5.7.5.1 Brazil
    • 5.7.5.2 Argentina
    • 5.7.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global Level Overview, Market Level Overview, Core Segments, Financials as Available, Strategic Information, Market Rank/Share for Key Companies, Products & Services, and Recent Developments)
  • 6.3.1 Antares Vision Group
  • 6.3.2 Arvato Supply Chain Solutions
  • 6.3.3 Avery Dennison Corporation
  • 6.3.4 Blue Yonder Group, Inc.
  • 6.3.5 Cardinal Health, Inc.
  • 6.3.6 Exostar, LLC
  • 6.3.7 Global Healthcare Exchange, LLC (GHX)
  • 6.3.8 IBM Corporation
  • 6.3.9 Infor Global Solutions
  • 6.3.10 Kinaxis Inc.
  • 6.3.11 Korber Pharma Software GmbH
  • 6.3.12 Manhattan Associates, Inc.
  • 6.3.13 McKesson Corporation
  • 6.3.14 Optel Group
  • 6.3.15 Oracle Corporation
  • 6.3.16 project44, Inc.
  • 6.3.17 SAP SE
  • 6.3.18 Tecsys Inc.
  • 6.3.19 TraceLink, Inc.
  • 6.3.20 UPS Healthcare

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-need Assessment